Johnson & Johnson Other Non-Current Liabilities 2012-2026 | JNJ
Johnson & Johnson other non-current liabilities from 2012 to 2026. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Johnson & Johnson other non-current liabilities for the quarter ending March 31, 2026 were $10.354B, a 42.28% decline year-over-year.
- Johnson & Johnson other non-current liabilities for 2025 were $10.354B, a 42.28% decline from 2024.
- Johnson & Johnson other non-current liabilities for 2024 were $17.939B, a 10.2% increase from 2023.
- Johnson & Johnson other non-current liabilities for 2023 were $16.279B, a 12.64% increase from 2022.
|
Johnson & Johnson Annual Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2025 | $10,354 |
| 2024 | $17,939 |
| 2023 | $16,279 |
| 2022 | $14,452 |
| 2021 | $16,399 |
| 2020 | $18,503 |
| 2019 | $19,178 |
| 2018 | $16,831 |
| 2017 | $17,489 |
| 2016 | $9,536 |
| 2015 | $10,241 |
| 2014 | $8,034 |
| 2013 | $7,854 |
| 2012 | $8,552 |
| 2011 | $10,631 |
|
Johnson & Johnson Quarterly Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2025-12-31 | $10,354 |
| 2025-09-30 | $10,344 |
| 2025-06-30 | $10,681 |
| 2025-03-31 | $10,830 |
| 2024-12-31 | $17,939 |
| 2024-09-30 | $15,277 |
| 2024-06-30 | $14,427 |
| 2024-03-31 | $17,948 |
| 2023-12-31 | $16,279 |
| 2023-09-30 | $16,102 |
| 2023-06-30 | $17,118 |
| 2023-03-31 | $18,717 |
| 2022-12-31 | $14,452 |
| 2022-09-30 | $14,080 |
| 2022-06-30 | $14,686 |
| 2022-03-31 | $16,242 |
| 2021-12-31 | $16,399 |
| 2021-09-30 | $16,947 |
| 2021-06-30 | $18,446 |
| 2021-03-31 | $18,509 |
| 2020-12-31 | $18,503 |
| 2020-09-30 | $18,894 |
| 2020-06-30 | $17,625 |
| 2020-03-31 | $18,346 |
| 2019-12-31 | $19,178 |
| 2019-09-30 | $18,874 |
| 2019-06-30 | $17,645 |
| 2019-03-31 | $17,002 |
| 2018-12-31 | $16,831 |
| 2018-09-30 | $17,075 |
| 2018-06-30 | $17,928 |
| 2018-03-31 | $18,329 |
| 2017-12-31 | $17,489 |
| 2017-09-30 | $9,102 |
| 2017-06-30 | $10,117 |
| 2017-03-31 | $9,526 |
| 2016-12-31 | $9,536 |
| 2016-09-30 | $9,414 |
| 2016-06-30 | $10,062 |
| 2016-03-31 | $9,749 |
| 2015-12-31 | $10,241 |
| 2015-09-30 | $9,303 |
| 2015-06-30 | $8,973 |
| 2015-03-31 | $8,604 |
| 2014-12-31 | $8,034 |
| 2014-09-30 | $7,758 |
| 2014-06-30 | $7,373 |
| 2014-03-31 | $7,271 |
| 2013-12-31 | $7,854 |
| 2013-09-30 | $8,895 |
| 2013-06-30 | $8,569 |
| 2013-03-31 | $8,197 |
| 2012-12-31 | $8,552 |
| 2012-09-30 | $9,207 |
| 2012-06-30 | $9,487 |
| 2012-03-31 | $10,538 |
| 2011-12-31 | $10,631 |
| 2011-09-30 | $7,473 |
| 2011-06-30 | $7,227 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |